Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AVBP

ArriVent BioPharma Inc

Dec 11 • 01:17PM ET

27.64

Dollar change -0.69
Percentage change -2.44	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN SRPT VRTX REGN MRNA BIIB GILD IONS NBIX BLUE

| Held by: VTI IWM VXF IWO VTWO SCHA IWN XBI IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.42	Insider Own	42.28%	Shs Outstand	33.69M	Perf Week	-5.50%
Market Cap	931.39M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	0.00%	Shs Float	19.45M	Perf Month	-19.49%
Income	-81.05M	PEG	-	EPS next Q	-0.78	Inst Own	57.75%	Short Float	17.01%	Perf Quarter	16.18%
Sales	0.00M	P/S	-	EPS this Y	91.67%	Inst Trans	36.12%	Short Ratio	13.45	Perf Half Y	48.12%
Book/sh	8.24	P/B	3.36	EPS next Y	-4.38%	ROA	-34.14%	Short Interest	3.31M	Perf Year	-
Cash/sh	8.39	P/C	3.29	EPS next 5Y	-	ROE	-36.06%	52W Range	14.35 - 36.37	Perf YTD	38.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-29.20%	52W High	-24.00%	Beta	-
Dividend TTM	-	Quick Ratio	19.28	Sales past 5Y	0.00%	Gross Margin	-	52W Low	92.61%	ATR (14)	1.51
Dividend Ex-Date	-	Current Ratio	19.28	EPS Y/Y TTM	-38.12%	Oper. Margin	-	RSI (14)	42.99	Volatility	4.56% 5.55%
Employees	40	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	38.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-41.93%	Payout	-	Rel Volume	0.20	Prev Close	28.33
Sales Surprise	-	EPS Surprise	39.16%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	246.02K	Price	27.64
SMA20	-2.70%	SMA50	-5.93%	SMA200	23.01%	Trades		Volume	29,906	Change	-2.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-24	Initiated	Oppenheimer	Outperform	$35
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

Nov-14-24 08:00AM	ArriVent BioPharma Reports Third Quarter 2024 Financial Results (GlobeNewswire) -11.86%
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc (GuruFocus.com)
Sep-09-24 12:05PM	ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer (GlobeNewswire)
Aug-19-24 09:55AM	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
Aug-14-24 09:54PM	AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Loading…
04:01PM	ArriVent BioPharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer (GlobeNewswire)
Jun-05-24 07:00AM	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab (GlobeNewswire)
May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaChapelle Robin	Chief Operating Officer	Sep 19 '24	Option Exercise	3.28	27,566	90,481	124,583	Sep 23 06:14 PM
HILLHOUSE INVESTMENT MANAGEMEN	10% Owner	Jan 30 '24	Buy	18.00	555,555	9,999,990	4,484,672	Feb 01 04:47 PM
ORBIMED ADVISORS LLC	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:12 PM
GORDON CARL L	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:11 PM
HEALY JAMES	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,696,752	Jan 31 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVBP

ArriVent BioPharma Inc

Upgrade your FINVIZ experience